This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Aug;62(8):2566.

doi: 10.1002/art.27557.

Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al

Lidia Rudnicka, Malgorzata Olszewska, Agnieszka Kardynal

PMID: 20496370
DOI: 10.1002/art.27557

Comment

Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al

Lidia Rudnicka et al. Arthritis Rheum. 2010 Aug.

. 2010 Aug;62(8):2566.

doi: 10.1002/art.27557.

Authors

Lidia Rudnicka, Malgorzata Olszewska, Agnieszka Kardynal

PMID: 20496370
DOI: 10.1002/art.27557

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Merrill JT, et al. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. Arthritis Rheum. 2010. PMID: 20039413 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information